{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:17Z","timestamp":1786649897957,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Acanthosis nigricans (AN) features thick, hyperpigmented skin in flexural areas, often indicating insulin resistance. Dermoscopy of AN demonstrates sulci cutis and crista cutis, and differentiates it from other pigmentary dermatoses. Comparative efficacy studies are lacking in the literature. This study evaluates the clinical and dermoscopic changes in AN treated with metformin and pioglitazone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A randomised open-label trial was conducted on consenting AN patients aged 18 years or older. Patients were randomized to receive either metformin 500mg twice a day or pioglitazone 7.5mg twice a day for 3 months. Clinical grading, anthropometric measurements, and dermoscopic features were compared at baseline and at study completion at 12 weeks using IBM SPSS v26.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sixty-five patients (mean age 35 years) were distributed between two groups. Both drugs significantly improved clinical grading from baseline to 12 weeks. Metformin notably reduced the body mass index (29.55 \u00b1 3.51 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      to 28.92 \u00b1 3.44 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and weight (76.58 \u00b1 10.21 kg to 74.64 \u00b1 10.30 kg) more than pioglitazone, but there were no significant differences in other parameters. Both drugs significantly changed dermoscopic parameters, including sulci cutis and hyperpigmented dots and globules, with no differences between them. Papillary projection morphology correlated significantly with clinical grading.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations:<\/jats:title>\n                    <jats:p>The limitations of this study include a relatively short study duration, and a lack of assessment of the effect of patient and disease-related factors on treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Metformin and pioglitazone both significantly improved AN clinically and dermoscopically, with no significant differences in efficacy between them. Metformin is more effective in reducing weight and body mass index, and is suitable for overweight patients. Pioglitazone is an alternative for those intolerant or unresponsive to metformin. Dermoscopic parameters can indicate early treatment response before visible clinical improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_643_24","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:00:19Z","timestamp":1766736019000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Dermoscopic Evaluation of the Effectiveness of Metformin versus Pioglitazone in Acanthosis Nigricans: A Randomised Controlled Trial"],"prefix":"10.4103","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9431-0983","authenticated-orcid":false,"given":"Jinisha","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, KLE Academy of Higher Education & Research Jawaharlal Nehru Medical College, Karnataka Lingayat Education Society Prabhakar Kore Hospital, Belgaum, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Doshi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, KLE Academy of Higher Education & Research Jawaharlal Nehru Medical College, Karnataka Lingayat Education Society Prabhakar Kore Hospital, Belgaum, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi Prashant","family":"Shete","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, KLE Academy of Higher Education & Research Jawaharlal Nehru Medical College, Karnataka Lingayat Education Society Prabhakar Kore Hospital, Belgaum, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balachandra","family":"Ankad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, S Nijalingappa Medical College and Research Centre, Bagalkot, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"R1-20251229","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/2229-5178.137765","article-title":"An approach to acanthosis nigricans","volume":"5","author":"Phiske","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"R2-20251229","first-page":"4133","article-title":"Acanthosis nigricans: To be or not to be afraid","volume":"17","author":"Popa","year":"2019","journal-title":"Oncol Lett"},{"key":"R3-20251229","doi-asserted-by":"crossref","first-page":"e14521","DOI":"10.1111\/dth.14521","article-title":"Therapeutic implications of dermoscopic findings in acanthosis nigricans: A clinical and histopathological study","volume":"33","author":"Pardeshi","year":"2020","journal-title":"Dermatol Ther"},{"key":"R4-20251229","first-page":"126","article-title":"Prevalence of acanthosis nigricans in a population attending a tertiary care centre in western India and its utility to detect metabolic syndrome","volume":"5","author":"Tank","year":"2022","journal-title":"Int J Health Clin Res"},{"key":"R5-20251229","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/CCID.S137527","article-title":"Current treatment options for acanthosis nigricans","volume":"11","author":"Patel","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6 Suppl","key":"R6-20251229","doi-asserted-by":"crossref","first-page":"82S","DOI":"10.1111\/1523-1747.ep12462293","article-title":"Excess insulin binding to insulin-like growth factor receptors: Proposed mechanism for acanthosis nigricans","volume":"98","author":"Cruz","year":"1992","journal-title":"J Invest Dermatol"},{"key":"R7-20251229","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12889-017-4041-1","article-title":"Prevalence and trends of metabolic syndrome among adults in the Asia-Pacific region: A systematic review","volume":"17","author":"Ranasinghe","year":"2017","journal-title":"BMC Public Health"},{"key":"R8-20251229","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2002-021786","article-title":"Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes","volume":"88","author":"Pavo","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20251229","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2337\/diacare.22.10.1655","article-title":"A quantitative scale of acanthosis nigricans","volume":"22","author":"Burke","year":"1999","journal-title":"Diabetes Care"},{"key":"R10-20251229","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/ijd.IJD_417_17","article-title":"Effectiveness and safety of metformin versus Canthex\u2122in patients with acanthosis nigricans: A randomized, double-blind controlled trial","volume":"64","author":"Sett","year":"2019","journal-title":"Indian J Dermatol"},{"key":"R11-20251229","first-page":"884","article-title":"Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: A pilot study","volume":"5","author":"Bellot-Rojas","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"R12-20251229","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/dom.15501","article-title":"The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Haber","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R13-20251229","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1210\/rp.56.1.265","article-title":"Insulin resistance and its treatment by thiazolidinediones","volume":"56","author":"Lebovitz","year":"2001","journal-title":"Recent Prog Horm Res"},{"key":"R14-20251229","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: The forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr Diab Rep"},{"key":"R15-20251229","first-page":"3534","article-title":"Pioglitazone induced weight changes in type 2 diabetic patients","author":"Ghosh","year":"2011","journal-title":"Int J Collab Res Intern Med Public Health"},{"key":"R16-20251229","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13098-017-0290-5","article-title":"Effects of pioglitazone therapy on blood parameters, weight and BMI: A meta-analysis","volume":"9","author":"Filipova","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"R17-20251229","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/idoj.IDOJ_855_20","article-title":"Clinico-investigative study of facial acanthosis nigricans","volume":"13","author":"Shah","year":"2022","journal-title":"Indian Dermatol Online J"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_643_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:41Z","timestamp":1786647581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_643_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_643_24","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2024-06-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}